<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00566462</url>
  </required_header>
  <id_info>
    <org_study_id>E2007-A001-226</org_study_id>
    <nct_id>NCT00566462</nct_id>
  </id_info>
  <brief_title>Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT</brief_title>
  <official_title>Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      This is a two-arm, double-blind, placebo-controlled study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopped due to lack of efficacy.&#xD;
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">December 1, 2008</completion_date>
  <primary_completion_date type="Actual">December 1, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Striatal [^123I]-Iodobenzamine (IBZM_ Binding Following a Single Dose Carbidopa/Levodopa Challenge for 15-hours at Baseline and Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Caudate and Putamen [^123I]-IBZM Binding Following a Single Dose Carbidopa/Levodopa Challenge for 15-hours at Baseline and Week 4</measure>
    <time_frame>Baseline and Week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>perampanel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perampanel</intervention_name>
    <description>2 mg/d for 14 days followed by 4 mg/d for 14 days</description>
    <arm_group_label>perampanel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Matching placebo for for 14 days followed by 4 mg/d for 14 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          1. Male or female patients with idiopathic PD fulfilling the United Kingdom Parkinson's&#xD;
             Disease Society Brain Bank (UKPDSBB) diagnostic criteria, with a good response to&#xD;
             levodopa. The requirement in the UKPDSBB Step 2 for prior brain imaging is at the&#xD;
             discretion of the investigator.&#xD;
&#xD;
               -  Clinical diagnosis of idiopathic Parkinson's disease (patients must have at least&#xD;
                  two of the three cardinal symptoms: resting tremor, rigidity, bradykinesia)&#xD;
&#xD;
               -  Hoehn and Yahr Stage II to IV.&#xD;
&#xD;
               -  Treatment with monotherapy of levodopa plus an aromatic acid decarboxylase&#xD;
                  inhibitor (carbidopa). The carbidopa/levodopa medication should be taken at least&#xD;
                  two times daily (excluding the bedtime/night time dose) up to a maximum of eight&#xD;
                  doses daily (including the bedtime/night time dose).&#xD;
&#xD;
               -  Intermittent use of either liquid forms of levodopa or subcutaneous apomorphine&#xD;
                  is permitted.&#xD;
&#xD;
               -  Age &gt;30 years of age&#xD;
&#xD;
               -  Women who are incapable of bearing children (e.g., clinically assessed as&#xD;
                  infertile, including surgically sterile) or who are practicing effective&#xD;
                  contraception (e.g., abstinence, intrauterine device or barrier method plus&#xD;
                  hormonal method).&#xD;
&#xD;
             Postmenopausal women may be recruited but must be amenorrheic for at least 1 year to&#xD;
             be considered. Women must have a negative serum beta-human chorionic gondotrophin&#xD;
             (β-HCG) test at the Screening Visit and a negative urine pregnancy test prior to&#xD;
             radiotracer administration on the day of each SPECT scanning session. Women must also&#xD;
             be willing to remain on their current form of contraception for the duration of the&#xD;
             study.&#xD;
&#xD;
          2. In the investigator's opinion, patients are able to complete the study and are capable&#xD;
             of giving full written informed consent.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Patients with any one of the following will be excluded:&#xD;
&#xD;
          1. Inability or unwillingness to undergo SPECT or other study procedures&#xD;
&#xD;
          2. Pregnant or lactating women&#xD;
&#xD;
          3. Atypical or drug-induced PD&#xD;
&#xD;
          4. Current treatment with dopamine agonists, MAO or COMT inhibitors, anticholinergics&#xD;
&#xD;
          5. Patients with a past (within 1 year) or present history of psychotic symptoms&#xD;
             requiring antipsychotic treatment. Patients may be taking antidepressant medication,&#xD;
             however, the dose must be stable for 4 weeks prior to the Baseline Visit. Use of&#xD;
             antipsychotic medication including clozapine and quetiapine is prohibited, even if the&#xD;
             indication is for movement disorders.&#xD;
&#xD;
          6. Current or prior treatment (within 4 weeks prior to Baseline Visit) with pergolide,&#xD;
             tolcapone, methyldopa, budipine, reserpine, seroquel, or the herbal dopamine agonist,&#xD;
             Mucuna Pruriens&#xD;
&#xD;
          7. Patients with current or prior treatment (within 4 weeks prior to the Baseline Visit)&#xD;
             with medication known to induce the enzyme cytochrome P450 3A4&#xD;
&#xD;
          8. Use of an investigational product within 4 weeks prior to randomization or patients&#xD;
             who have participated in a previous study with perampanel&#xD;
&#xD;
          9. Patients with a past or present history of drug or alcohol abuse as per Diagnostic and&#xD;
             Statistical Manual - 4th edition (DSM IV) criteria&#xD;
&#xD;
         10. Dementia (as defined by a MMSE score of ≤ 24) and/or fulfilling the criteria for&#xD;
             dementia due to PD (as defined by the Diagnostic and Statistical Manual of the&#xD;
             American Psychiatric Association - 4th Edition)&#xD;
&#xD;
         11. Clinically significant unstable medical or psychiatric illness&#xD;
&#xD;
         12. Presence of physical, mental, or social condition that precludes informed consent or&#xD;
             interferes with careful follow-up&#xD;
&#xD;
         13. Past (within 1 year) or present history of suicidal ideation or suicide attempts&#xD;
&#xD;
         14. Elevations of liver enzymes, alanine aminotransferase (ALT), and aspartate&#xD;
             aminotransferase (AST) ≥ 1.5 times the upper limit of normal (ULN)&#xD;
&#xD;
         15. Patients with unstable abnormalities of the hepatic, renal, cardiovascular,&#xD;
             respiratory, gastrointestinal, haematological, endocrine, or metabolic systems that&#xD;
             might complicate assessment of the tolerability of the study medication&#xD;
&#xD;
         16. Evidence of significant active hematological disease: white blood cell (WBC) count ≤&#xD;
             2500/μL; absolute neutrophil count ≤ 1000/μL&#xD;
&#xD;
         17. Patients with previous stereotactic surgery (eg, pallidotomy) for Parkinson's disease&#xD;
             or with planned stereotactic surgery during the study period&#xD;
&#xD;
         18. Patients receiving or planning to receive (within 3 months) deep brain stimulation&#xD;
&#xD;
         19. Patients with conditions affecting the peripheral or central sensory system unless&#xD;
             related to Parkinson's disease (such as mild sensory or pain syndromes limited to&#xD;
             &quot;OFF&quot; periods) that could interfere with the evaluation of any such symptoms caused by&#xD;
             the study drug&#xD;
&#xD;
         20. Patients with any condition that would make the patient, in the opinion of the&#xD;
             investigator, unsuitable for the study&#xD;
&#xD;
         21. Patients with clinically significant ECG abnormality, including prolonged QTc (defined&#xD;
             as QTc &gt; 450 msec)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia Cole, PhD, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kenneth Marek</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Molecular NeuroImaging, LLC</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>inVentiv</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>November 29, 2007</study_first_submitted>
  <study_first_submitted_qc>November 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2007</study_first_posted>
  <results_first_submitted>November 20, 2012</results_first_submitted>
  <results_first_submitted_qc>November 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 24, 2012</results_first_posted>
  <last_update_submitted>September 5, 2018</last_update_submitted>
  <last_update_submitted_qc>September 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Perampanel</title>
          <description>A single dose carbidopa/levodopa (37.5mg/150mg PO) challenge at Baseline, followed by one 2-mg tablet/day PO of Perampanel for 14 days, then two 2-mg tablets/day (4-mg/day)PO of Perampanel for 14 days, followed by a single dose carbidopa/levodopa (37.5mg/150mg PO) challenge after 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>A single dose carbidopa/levodopa (37.5mg/150mg PO) challenge at Baseline, followed by one 2-mg tablet/day PO of perampanel-matched placebo for 14 days, then two 2-mg tablets/day (4-mg/day)PO of perampanel-matched placebo for 14 days, followed by a single dose carbidopa/levodopa (37.5mg/150mg PO) challenge after 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Perampanel</title>
          <description>A single dose carbidopa/levodopa (37.5mg/150mg PO) challenge at Baseline, followed by one 2-mg tablet/day PO of Perampanel for 14 days, then two 2-mg tablets/day (4-mg/day)PO of Perampanel for 14 days, followed by a single dose carbidopa/levodopa (37.5mg/150mg PO) challenge after 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>A single dose carbidopa/levodopa (37.5mg/150mg PO) challenge at Baseline, followed by one 2-mg tablet/day PO of perampanel-matched placebo for 14 days, then two 2-mg tablets/day (4-mg/day)PO of perampanel-matched placebo for 14 days, followed by a single dose carbidopa/levodopa (37.5mg/150mg PO) challenge after 4 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Striatal [^123I]-Iodobenzamine (IBZM_ Binding Following a Single Dose Carbidopa/Levodopa Challenge for 15-hours at Baseline and Week 4</title>
        <time_frame>Baseline and Week 4</time_frame>
        <population>No data was collected because the study was terminated at the sponsor request due to low enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Perampanel</title>
            <description>A single dose carbidopa/levodopa (37.5mg/150mg PO) challenge at Baseline, followed by one 2-mg tablet/day PO of Perampanel for 14 days, then two 2-mg tablets/day (4-mg/day)PO of Perampanel for 14 days, followed by a single dose carbidopa/levodopa (37.5mg/150mg PO) challenge after 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single dose carbidopa/levodopa (37.5mg/150mg PO) challenge at Baseline, followed by one 2-mg tablet/day PO of perampanel-matched placebo for 14 days, then two 2-mg tablets/day (4-mg/day)PO of perampanel-matched placebo for 14 days, followed by a single dose carbidopa/levodopa (37.5mg/150mg PO) challenge after 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Striatal [^123I]-Iodobenzamine (IBZM_ Binding Following a Single Dose Carbidopa/Levodopa Challenge for 15-hours at Baseline and Week 4</title>
          <population>No data was collected because the study was terminated at the sponsor request due to low enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Caudate and Putamen [^123I]-IBZM Binding Following a Single Dose Carbidopa/Levodopa Challenge for 15-hours at Baseline and Week 4</title>
        <time_frame>Baseline and Week 4</time_frame>
        <population>No data was collected because the study was terminated at the sponsor request due to low enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Perampanel</title>
            <description>A single dose carbidopa/levodopa (37.5mg/150mg PO) challenge at Baseline, followed by one 2-mg tablet/day PO of Perampanel for 14 days, then two 2-mg tablets/day (4-mg/day)PO of Perampanel for 14 days, followed by a single dose carbidopa/levodopa (37.5mg/150mg PO) challenge after 4 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>A single dose carbidopa/levodopa (37.5mg/150mg PO) challenge at Baseline, followed by one 2-mg tablet/day PO of perampanel-matched placebo for 14 days, then two 2-mg tablets/day (4-mg/day)PO of perampanel-matched placebo for 14 days, followed by a single dose carbidopa/levodopa (37.5mg/150mg PO) challenge after 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Caudate and Putamen [^123I]-IBZM Binding Following a Single Dose Carbidopa/Levodopa Challenge for 15-hours at Baseline and Week 4</title>
          <population>No data was collected because the study was terminated at the sponsor request due to low enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Perampanel</title>
          <description>A single dose carbidopa/levodopa (37.5mg/150mg PO) challenge at Baseline, followed by one 2-mg tablet/day PO of Perampanel for 14 days, then two 2-mg tablets/day (4-mg/day)PO of Perampanel for 14 days, followed by a single dose carbidopa/levodopa (37.5mg/150mg PO) challenge after 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>A single dose carbidopa/levodopa (37.5mg/150mg PO) challenge at Baseline, followed by one 2-mg tablet/day PO of perampanel-matched placebo for 14 days, then two 2-mg tablets/day (4-mg/day)PO of perampanel-matched placebo for 14 days, followed by a single dose carbidopa/levodopa (37.5mg/150mg PO) challenge after 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Low Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Frontal Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sore Tongue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated at the sponsor request after only 1 subject was enrolled and completed the study and therefore the data is limited. Similiar research in this area have required a minimum of 5-6 completers to develop a valid analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Eisai Inc.</name_or_title>
      <organization>Eisai Call Center</organization>
      <phone>888-422-4743</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

